Africa Western and Central vs United Kingdom: Access to anti-retroviral drugs, female
Africa Western and Central
83.1%
in 2024
United Kingdom
96.0%
in 2023
Africa Western and Central rank
14th
United Kingdom rank
14th
Access to anti-retroviral drugs, female over time
- Africa Western and Central
- United Kingdom
How they compare
United Kingdom currently reports 96.0% against 83.1% in Africa Western and Central, a difference of 12.9%.
That makes United Kingdom's figure about 1.2 times Africa Western and Central's.
Across all 8 years both countries report, United Kingdom has been ahead every year.
Africa Western and Central ranks 14th and United Kingdom ranks 14th of 19 groups.
United Kingdom has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Africa Western and Central | United Kingdom | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 53.9% | 88.0% | 34.1% | United Kingdom |
| 2020s | 72.5% | 90.8% | 18.3% | United Kingdom |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Africa Western and Central or United Kingdom?
- United Kingdom, at 96.0% against 83.1% in Africa Western and Central as of 2023.
- What is the difference in access to anti-retroviral drugs, female between Africa Western and Central and United Kingdom?
- 12.9%, with United Kingdom ahead.
- How many years of comparable data are there for Africa Western and Central and United Kingdom?
- 8 years are reported by both, from 2016 to 2023.
- How do Africa Western and Central and United Kingdom rank globally for access to anti-retroviral drugs, female?
- Africa Western and Central ranks 14th and United Kingdom ranks 14th of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.